MRPL, Gland, Dixon Technologies among top gainers on Nifty Midcap 150

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

In Wednesday's session, several stocks showed strong performance within the Nifty Midcap 150 index. MRPL, Gland Pharma, and Dixon Technologies were among the top gainers. MRPL's shares led the pack with over 6% increase.

Gland Pharma followed, with its stock gaining 3%. Dixon Technologies also saw a notable rise, increasing by nearly 3%. Rounding out the top gainers were Max Healthcare and One 97 Communications.

MRPL Financial Performance

MRPL's financial performance shows varied results across the quarters. The company's consolidated revenue for the quarter-ending June 2025 was Rs 17,356.23 Crore, compared to Rs 23,247.02 Crore in June 2024. Net profit for the same period was a loss of Rs 271.97 Crore, a significant downturn from a profit of Rs 65.57 Crore in the previous year.

MRPL Quarterly Income Statement (Consolidated)

MRPL Annual Income Statement (Consolidated)

The annual revenue for the year ending March 2025 increased to Rs 94,681.62 Crore from Rs 90,406.68 Crore in the previous year. However, the net profit saw a steep decline, falling to Rs 28.08 Crore in March 2025 from Rs 3,582.44 Crore in March 2024.

Gland Pharma Financials

Gland Pharma's financial results show a strong yearly performance but mixed quarterly results. The consolidated revenue for the quarter ending March 2025 was Rs 1,424.91 Crore, compared to Rs 1,537.45 Crore in March 2024. The net profit for the same period was Rs 186.54 Crore, slightly down from Rs 192.42 Crore in the previous year.

Gland Pharma Quarterly Income Statement (Standalone)

Gland Pharma Annual Income Statement (Standalone)

The annual revenue for the year ending March 2025 was Rs 5,616.50 Crore compared to Rs 5,664.72 Crore in the previous year. The net profit decreased from Rs 772.46 Crore in March 2024 to Rs 698.53 Crore in March 2025.

Dixon Technologies Financials

Dixon Technologies' financial performance highlights strong yearly growth, with positive but fluctuating quarterly results. The consolidated revenue for the quarter ending June 2025 was Rs 12,835.66 Crore, up from Rs 6,579.80 Crore in June 2024. The net profit for the same period was Rs 273.26 Crore, compared to Rs 132.26 Crore in the previous year.

Dixon Technologies Quarterly Income Statement (Consolidated)

Dixon Technologies Annual Income Statement (Consolidated)

The annual revenue for the year ending March 2025 significantly increased to Rs 38,860.10 Crore from Rs 17,690.90 Crore in the previous year. The net profit also rose sharply to Rs 1,215.20 Crore in March 2025 from Rs 364.68 Crore in March 2024.

MRPL has announced several corporate actions, including amendments to the Memorandum of Association. Gland Pharma will hold an earnings call on August 5, 2025, to discuss financial results. Dixon Technologies has diversified its business, according to a recent exchange filing. One 97 Paytm has approved the grant of stock options under its ESOP scheme.

Moneycontrol's analysis on July 21, 2025, indicated a bearish sentiment for the stock.